2 unchanged sentences
Our common stock, $0.00001 par value per share, is traded on Nasdaq under the symbol “ZYME.” Prior to December 16, 2022, our common stock was traded on the NYSE under the symbol “ZYME.”
−Removed: As of March 3, 2025, we had 80 stockholders of record holding our common stock.
+Added: As of February 26, 2026, we had 72 stockholders of record holding our common stock.
A substantially greater number of holders of Zymeworks’ common stock are “street name” or beneficial holders whose shares of record are held by banks, brokers, and other financial institutions.
5 unchanged sentences
Recent Sales of Unregistered Securities
−Removed: We di d not sell securities without registration under the Securities Act during the fiscal year ended December 31, 2024.
+Added: Except as previously disclosed, we di d not sell securities without registration under the Securities Act during the fiscal year ended December 31, 2025.
Issuer Repurchases of Equity Securities
−Removed: On August 1, 2024, our board of directors authorized the Repurchase Program, whereby we may repurchase up to $60.0 million of our outstanding common stock, par value $0.00001 per share.
−Removed: In the fourth quarter of 2024, shares of common stock purchased under the authorization consisted of the following:
+Added: On August 1, 2024, our board of directors authorized a stock repurchase program ( “ 2024 Repurchase Program ”) , whereby we could repurchase up to $60.0 million of our outstanding common stock.
+Added: As of October 31, 2024, we completed the initial $30.0 million of the 2024 Repurchase Program, consisting of the repurchase of 2,545,402 shares at an average price per share of $11.79 (exclusive of commission expense and estimated e xcise tax).
+Added: As of November 10, 2025, we completed the remaining $30.0 million of the 2024 Repurchase Program, consisting of the repurchase of 1,856,907 shares at an average price per share of $16.15 (exclusive of commission expense and estimated excise tax).
+Added: On November 16, 2025, our board of directors authorized a new stock repurchase program (the “2025 Repurchase Program”), whereby we may repurchase up to $125.0 million of our outstanding common stock.
+Added: As of December 31, 2025, we repurchased an aggregate of $11.2 million, consisting of 431,217 shares at an average price per share of $25.94 (exclusive of commission expense and estimated excise tax).
+Added: Table o f Contents
+Added: In the fourth quarter of 2025, shares of common stock purchased under the authorizations consisted of the following:
Total number of shares purchased
1 unchanged sentence
Total number of shares purchased as part of publicly announced plans or programs
−Removed: Approximate dollar value of shares that may yet be purchased under publicly announced plans or programs (in millions)
+Added: Dollar value of shares that may yet be purchased under publicly announced plans or programs (in millions)
October 1, 2025 - October 31, 2025
+Added: 410,735 17.16 410,735 7.3
November 1, 2025 - November 30, 2025
+Added: 478,043 18.21 478,043 123.6
December 1, 2025 - December 31, 2025
1 unchanged sentence
1,259,791 $ 20.24 1,259,791 $ 113.8
+Added: ________________________
(1) Average price paid per share excludes commission expense and estimated excise tax.
−Removed: As of October 31, 2024, we completed the initial $30.0 million of the Repurchase Program for 2,545,402 shares of our common stock at an average price per share of $11.79 (exclusive of commission expense and estimated exci se tax).
+Added: Table o f Contents
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.